Telix Pharmaceuticals (ASX:TLX; NASDAQ:TLX) saw its shares decline 3.03% to A$17.31 in early Sydney trading on Monday, following the announcement of a significant acquisition. The company has agreed to buy private German radiopharmaceutical firm ITM in a deal valued at US$1.65 billion upfront, payable primarily in stock.
Under the terms, ITM shareholders will receive 105.8 million newly issued Telix shares, representing a 23.7% ownership stake in the enlarged company once the transaction closes. The all-stock structure protects Telix's cash reserves—US$252 million as of June—but dilutes existing shareholders by 31.1%.
The acquisition is a strategic move to vertically integrate isotope supply, a critical component in radiopharmaceutical manufacturing. ITM, a profitable supplier of lutetium-177 and other isotopes across more than 65 countries, generated US$273 million in revenue in 2025. Telix CEO Christian Behrenbruch highlighted that the deal "further expands our late-stage therapeutic pipeline" and strengthens isotope security.
Investors, however, are focused on the immediate dilution. The stock opened at A$17.10 and traded in a range of A$16.82 to A$17.40, with volume of 343,590 shares in the first two minutes—16.2% of the average daily volume. Despite the decline, the share price remains 4.0% above the deal's pricing reference of A$16.65, based on the 30-day VWAP.
The total consideration includes US$1.25 billion in shares, US$302 million in assumed net debt, and US$96 million in seller expenses and rollover. Additionally, up to US$700 million in contingent payments could be made in cash or shares, dependent on regulatory approvals and sales of ITM-11, a key pipeline asset. The upfront price equates to roughly 6.0 times ITM's 2025 revenue.
Telix's financials show H1 2026 revenue of US$477 million and operating cash flow of US$223 million. The company has guided to FY2026 revenue of US$950-970 million. Combined with ITM, pro forma revenue for 2026 is expected to exceed US$1.3 billion, with a positive EBITDA contribution anticipated in 2027.
Analysts had been bullish on Telix before the deal, with an average price target of A$23.52, representing 35.9% upside. However, these targets do not yet incorporate the new shares, debt, or ITM's earnings. Key risks include integration challenges, potential future supply from escrowed sellers, and regulatory/commercial success of ITM-11, which has completed one Phase 3 trial with another readout expected in H1 2027.
Investors will get more clarity at Telix's R&D day on September 22, and a shareholder meeting is expected in November to approve the transaction.
